CELLAVISION AB (publ) - Year-End Bulletin 2009
(Thomson Reuters ONE) - Third consecutive year of profitabilityJanuary - December * Net sales increased by 8 % to SEK 109.0 million (100.4) * The operating result increased to SEK 14.8 million (13.4) * Profit before income tax increased to SEK 14.2 million (13.1) * The net result per share amounted to SEK 1.16 (1.05) * Cash and cash equivalents amounted to SEK 22.0 million (19.6) by the end of the year * Gross profit was 70 % (63) during the year * Strengthened presence on markets in the US, Canada, and Japan * Strong initial sales of the new CellaVision® DM1200 analyzer in Europe and North America * CellaVision was awarded the SwedenBIO Award 2009October - December * Net sales for the fourth quarter amounted to SEK 39.3 million (38.3) * The operating result amounted to SEK 7.5 million (7.1)Important events after the end of the year * CellaVision expanded distribution channels in the US through an agreement with Beckman Coulter * The Board of Directors of CellaVision plans to apply for a listing on NASDAQ OMX Small Cap during the first half of 2010 CellaVision in short (MSEK) Q4 2009 Q4 2008 Year 2009 Year 2008 Net sales 39.3 38.3 109.0 100.4 Gross profit 25.5 21.1 76.5 63.5 Operating result 7.5 7.1 14.8 13.4 Profit before tax 7.4 7.0 14.2 13.1 Cash flow 10.0 8.3 2.3 3.3CEO's commentIt is very pleasing to look back at another year of profitability, says YvonneM?ensson, CEO of CellaVision. During the year we have continued to invest inour subsidiaries in the US, Canada and Japan by recruiting more personnel andenhancing market activities, making the company more visible and continuing thepenetration of these important markets. For the first time in CellaVisionhistory net sales were higher in North America than in Europe. Our new analyzer,the DM1200, was launched in Europe and Canada and will soon be available on theUS market, and we have entered an agreement with an additional globaldistributor, Beckman Coulter. These are all steps towards strengthening ourposition as market leading in image analysis for hematology laboratories. We arewell prepared for the challenges that await us in 2010 in our ambition forachieving continued growth.For more information please contact:Yvonne M?ensson, CEO. Phone: +46 708 33 77 82, e-mail:yvonne.martensson(at)cellavision.se
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.02.2010 - 02:32 Uhr
Sprache: Deutsch
News-ID 1010327
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Lund
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 108 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CELLAVISION AB (publ) - Year-End Bulletin 2009
"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
